Cannabis Law Report

JUNE 21, 2021

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: Two Case Presentations.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Otherside Farms

JANUARY 24, 2019

In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S. Cilio will also conduct two individual studies of the drug.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JULY 7, 2021

The country, which Tilray said has an estimated medical marijuana demand of more than 100,000 patients, legalized the drug for medical use in 2017 but has since relied on importing it. What they’re asking is … for information,” she said, like how the products are used, how patients can be instructed, and what dosage is. “We

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

SpeedWeed

AUGUST 11, 2021

This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We MAPS Makes History.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

AUGUST 17, 2021

Technology licensing should be on the radar for pharmaceutical companies offering drugs for respiratory diseases. Improving Patient Outcomes with Real-time Feedback via Smart Inhalers and Portable and Lightweight Oxygen Concentrators for Increasing Home-Based Therapy is a Key Growth Opportunity. The Strategic Imperative. Cognita Labs.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. The harvest includes the following psilocybin-containing mushroom strains: Koh Samui. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

SEPTEMBER 14, 2021

Comprehensive health-related outcome data from study participants, that is inclusive of highly diverse demographics and behavioral habits, further enables brands to deliver targeted formulations to specific customer segments. Step five: The OBX and Radicle Science validated product is sent to production.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

JULY 29, 2021

The Medical Division is launching its first six Opitcann medical “CB4” line of branded products to be sold through medical channel partners and through Heritage Patient Care starting in August 2021.

Recreational 98

Recreational Vaping Concentrates Clinical Trials 98

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Develop and maintain the Core Data Sheet and lead global labeling team meetings. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

DECEMBER 17, 2021

deletion syndrome patient pool and forecasted trend for each seven major countries. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. Emerging Drugs.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JULY 6, 2021

Dr. Bankole Johnson was also the founder of NASDAQ listed Adial Pharmaceuticals (NASDAQ: ADIL) and currently serves as its Chief Medical Officer. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.” ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

CannaMD

NOVEMBER 6, 2019

Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.

Marijuana 88

Marijuana Patients Clinical Trials Data 88

Cannabis Law Report

AUGUST 10, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About MyMD Pharmaceuticals, Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Greencamp

FEBRUARY 2, 2019

Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. How classical pharmaceuticals fight HIV. Cannabis as a palliative aid for HIV patients. What is HIV and how is it manifested?

Marijuana 110

Marijuana Therapy Cannabinoids Patients 110

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. Ultimately, cannabis for mental health seems to boil down to questions of individual patient suitability. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66